Seminars in Diagnostic Pathology
Volume 25, Issue 4 , Pages 262-273 , November 2008

Targeted therapies in gynecologic cancers and melanoma

References 

  1. Moreno–Bueno G, Sánchez–Estévez C, Cassia R, et al. Differential gene expression profile in endometrioid and nonendometrioid endometrial carcinoma: STK15 is frequently overexpressed and amplified in nonendometrioid carcinomas. Cancer Res. 2003;63:5697–5702
  2. Bockman JV. Two pathogenetic types of endometrial carcinoma. Gynecol Oncol. 1983;15:10–17
  3. Lax SF, Kurman RJ. A dualistic model for endometrial carcinogenesis based on immunohistochemical and molecular genetic analyses. Verh Dtsch Ges Pathol. 1997;81:228–232
  4. Matias–Guiu X, Catasus L, Bussaglia E, et al. Molecular pathology of endometrial hyperplasia and carcinoma. Hum Pathol. 2001;32:569–577
  5. Catasús Ll, Machin P, Matias–Guiu X, et al. Microsatellite instability in endometrial carcinomas clinicopathologic correlations in a series of 42 cases. Human Pathol. 1998;29:1160–1164
  6. Bussaglia E, del Rio E, Matias–Guiu X, et al. PTEN mutations in endometrial carcinomas (A molecular and clinicopathologic analysis of 38 cases). Hum Pathol. 2000;31:312–317
  7. Velasco A, Bussaglia E, Pallares J, et al. PIK3CA gene mutations in endometrial carcinoma: correlation with PTEN and K-RAS alterations. Hum Pathol. 2006;37:1465–1472
  8. Machin P, Catasus L, Pons C, et al. CTNNB1 mutations and beta-catenin expression in endometrial carcinomas. Hum Pathol. 2002;33:206–212
  9. Moreno–Bueno G, Hardisson D, Sánchez C, et al. Abnormalities of the APC/beta-catenin pathway in endometrial cancer. Oncogene. 2002;21:7981–7990
  10. Tashiro H, Isacson C, Levine R, et al. p53 gene mutations are common in uterine serous carcinoma and occurs early in their pathogenesis. Am J Pathol. 1997;150:177–185
  11. Sherman ME, Bur ME, Kurman RJ. p53 in endometrial cancer and its putative precursors: evidence for diverse pathways of tumorigenesis. Hum Pathol. 1995;26:1268–1274
  12. Mutter GL, Lin MC, Fitzgerald JT, et al. Altered PTEN expression as a diagnostic marker for the earliest endometrial precancers. J Natl Cancer Inst. 2000;92:924–931
  13. Levine RL, Cargile CB, Blazes MS, et al. PTEN mutations and microsatellite instability in complex atypical hyperplasia, a precursor lesion to uterine endometrioid carcinoma. Cancer Res. 1998;58:3254–3258
  14. Oda K, Stokoe D, Taketani Y, et al. High frequency of coexistent mutations of PIK3CA and PTEN genes in endometrial carcinoma. Cancer Res. 2005;65:10669–10673
  15. Gagnon V, St-Germain ME, Parent S, et al. Akt activity in endometrial cancer cells: regulation of cell survival through cIAP-1. Int J Oncol. 2003;23:803–810
  16. Chon HS, Hu W, Kavanagh JJ. Targeted therapies in gynecologic cancers. Curr Cancer Drug Targets. 2006;6:333–363
  17. Podsypanina K, Lee RT, Politis C, et al. An inhibitor of mTOR reduces neoplasia and normalizes p70/S6 kinase activity in Pten+/− mice. Proc Natl Acad Sci U S A. 2001;98:10320–10325
  18. Khalifa MA, Abdoh AA, Mannel RS, et al. Prognostic utility of epidermal growth factor receptor overexpression in endometrial adenocarcinoma. Cancer. 1994;73:370–376
  19. Morrison C, Zanagnolo V, Ramirez N, et al. HER-2 is an independent prognostic factor in endometrial cancer: association with outcome in a large cohort of surgically staged patients. J Clin Oncol. 2006;24:2376–2385
  20. Pallares J, Martinez–Guitarte JL, Dolcet X, et al. Abnormalities in NF-kB family and related proteins in endometrial carcinoma (A tissue microarray study). J Pathol. 2004;13:569–577
  21. Catasús L, Matias–Guiu X, Machin P, et al. BAX somatic frameshift mutations in endometrioid adenocarcinomas of the endometrium: evidence for a tumor progression role in endometrial carcinomas with microsatellite instability. Lab Invest. 1998;78:1439–1444
  22. Dolcet X, Llobet D, Encinas M, et al. Proteasome inhibitors induce death but activate NF-kappaB on endometrial carcinoma cell lines and primary culture explants. J Biol Chem. 2006;281:22118–22130
  23. Llobet D, Eritja N, Encinas M, et al. Antioxidants block proteasome inhibitor function in endometrial carcinoma cells. Anticancer Drugs. 2008;19:115–124
  24. Dolcet X, Llobet D, Pallares J, et al. FLIP is frequently expressed in endometrial carcinoma and has a role in resistance to TRAIL-induced apoptosis. Lab Invest. 2005;85:885–894
  25. Llobet D, Eritja N, Encinas M, et al. CK2 controls TRAIL and Fas sensitivity by regulating FLIP levels in endometrial carcinoma cells. Oncogene. 2008;27:2513–2524
  26. Gunin AG, Kapitova IN, Suslonova NV. Effects of histone deacetylase inhibitors on estradiol-induced proliferation and hyperplasia formation in the mouse uterus. J Endocrinol. 2005;185:539–549
  27. Takai N, Desmond JC, Kumagai T, et al. Histone deacetylase inhibitors have a profound antigrowth activity in endometrial cancer cells. Clin Cancer Res. 2004;10:1141–1149
  28. Matias–Guiu X, Prat J. Molecular pathology of ovarian carcinomas. Virchows Arch. 1998;433:103–111
  29. Kurman RJ, Shih IeM. Pathogenesis of ovarian cancer: lessons from morphology and molecular biology and their clinical implications. Int J Gynecol Pathol. 2008;27:151–160
  30. Esteller M, Silva JM, Dominguez G, et al. Promoter hypermethylation and BRCA1 inactivation in sporadic breast and ovarian tumors. J Natl Cancer Inst. 2000;92:564–569
  31. Gras E, Cortes J, Diez O, et al. Loss of heterozygosity on chromosome 13q12-q14, BRCA-2 mutations and lack of BRCA-2 promoter hypermethylation in sporadic epithelial ovarian tumors. Cancer. 2001;92:787–795
  32. Gras E, Catasus L, Argüelles R, et al. Microsatellite instability, MLH-1 promoter hypermethylation, and frameshift mutations at coding mononucleotide repeat microsatellites in ovarian tumors. Cancer. 2001;92:2829–2836
  33. Tsuchiya A, Sakamoto M, Yasuda J, et al. Expression profiling in ovarian clear cell carcinoma: identification of hepatocyte nuclear factor-1 beta as a molecular marker and a possible molecular target for therapy of ovarian clear cell carcinoma. Am J Pathol. 2003;163:2503–2512
  34. Cuatrecasas M, Villanueva A, Matias–Guiu X, et al. K-ras mutations in mucinous ovarian tumors: a clinicopathologic and molecular study of 95 cases. Cancer. 1997;79:1581–1586
  35. Burger RA, Sill M, Monk BJ, et al. Phase II trial of bevacizumab in persisntent or recurrent epithelail ovarian cancer or primary peritoneal cancer (A Gynecologic Oncology Group study (abstract)). J Clin Oncol. 2005;23:457s
  36. Palayekar MJ, Herzog TJ. The emerging role of epidermal growth factor receptor inhibitors in ovarian cancer. Int J Gynecol Cancer. 2007;Dec 5 [Epub ahead of print]
  37. Bookman MA, Darcy KM, Clarke–Pearson D, et al. Evaluation of monoclonal humanized anti-HER2 antibody, trastuzumab, in patients with recurrent or refractory ovarian or primary peritoneal carcinoma with overexpression of HER2: a phase II trial of the Gynecologic Oncology Group. J Clin Oncol. 2003;21:283–290
  38. Gordon MS, Matei D, Aghajanian C, et al. Clinical activity of pertuzumab (rhuMAb 2C4), a HER dimerization inhibitor, in advanced ovarian cancer: potential predictive relationship with tumor HER2 activation status. J Clin Oncol. 2006;24:4324–4332
  39. Dharap SS, Chandna P, Wang Y, et al. Molecular targeting of BCL2 and BCLXL proteins by synthetic BCL2 homology 3 domain peptide enhances the efficacy of chemotherapy. J Pharmacol Exp Ther. 2006;316:992–998
  40. Mross K, Steinbild S, Baas F, et al. Results from an in vitro and a clinical/pharmacological phase I study with the combination irinotecan and sorafenib. Eur J Cancer. 2007;43:55–63
  41. Hussein MR. Genetic pathways to melanoma tumorogenesis. J Clin Pathol. 2004;57:797–801
  42. Newton Bishop JA, Gruis NA. Genetics: what advice for patients who present with a family history of melanoma?. Semin Oncol. 2007;34:452–459
  43. Curtin JA, Fridlyand J, Tageshita T, et al. Distinct sets of genetic alterations in melanoma. N Engl J Med. 2005;353:2135–2147
  44. Curtin JA, Busam K, Pinkel D, et al. Somatic activation of KIT in distinct subtypes of melanoma. J Clin Oncol. 2006;24:4340–4346
  45. Thompson JF, Scolyer RA, Kefford RF. Cutaneous melanoma. Lancet. 2005;365:687–701
  46. Lorigan P, Eisen T, Hauschild A. Systemic therapy for metastatic malignant melanoma–from deeply disappointing to bright future?. Exp Dermatol. 2008;17:383–394
  47. Fecher LA, Amaravadi RK, Flaherty KT. The MAPK pathway in melanoma. Curr Opin Oncol. 2008;20:183–189
  48. Gray Shopfer VC, da Rocha Dias S, Marais R. The role of B-RAF in melanoma. Cancer Metastasis Rev. 2005;24:165–183
  49. Panka DJ, Wang W, Atkins MB, et al. The Raf inhibitor BAY 43-9006 (Sorafenib) induces caspase-independent apoptosis in melanoma cells. Cancer Res. 2006;66:1611–1619
  50. Eisen T, Ahmad T, Flahery KT, et al. Sorafenib in advanced melanoma: a Phase II randomised discontinuation trial analysis. Br J Cancer. 2006;95:581–586
  51. McDermott DF, Sosman JA, Gonzalez R, et al. Double-blind randomized phase II study of the combination of sorafenib and dacarbazine in patients with advanced melanoma: a report from the 11715 Study Group. J Clin Oncol. 2008;26:2178–2185
  52. Abi–Habib RJ, Urieto JO, Liu S, et al. BRAF status and mitogen-activated protein/extracellular signal-regulated kinase kinase 1/2 activity indicate sensitivity of melanoma cells to anthrax lethal toxin. Mol Cancer Ther. 2005;4:1303–1310
  53. Robertson GP. Functional and therapeutic significance of Akt deregulation in malignant melanoma. Cancer Metastasis Rev. 2005;24:273–285
  54. Chan S. Targeting the mammalian target of rapamycin (mTOR): a new approach to treating cancer. Br J Cancer. 2004;91:1420–1424
  55. Mayorga ME, Sanchis D, Perez de Santos AM, et al. Antiproliferative effect of STI571 on cultured human cutaneous melanoma-derived cell lines. Melanoma Res. 2006;16:127–135
  56. Grossman D. Imatinib mesylate for melanoma: will a new target be revealed?. J Invest Dermatol. 2004;123:xi–xiii
  57. Lefevre G, Glotin AL, Calipel A, et al. Roles of stem cell factor/c-kit and effects of Glivec(R)/STI571 in human uveal melanoma cell tumorigenesis. J Biol Chem. 2004;23:31769–31779
  58. Amiri KI, Horton LW, LaFleur BJ, et al. Augmenting chemosensitivity of malignant melanoma tumors via proteasome inhibition: implication for bortezomib (VELCADE. PS-341) as a therapeutic agent for malignant melanoma. Cancer Res. 2004;64:4912–4918
  59. Sorolla A, Yeramian A, Dolcet X, et al. Effect of proteasome inhibitors on proliferation and apoptosis of human cutaneous melanoma-derived cell lines. Br J Dermatol. 2008;158:496–504
  60. Bedikian AY, Millward M, Pehamberger H, et al. Bcl-2 antisense (oblimersen sodium) plus dacarbazine in patients with advanced melanoma: the Oblimersen Melanoma Study Group. J Clin Oncol. 2006;24:4738–4745
  61. Moreira JN, Santos A, Simões S. Bcl-2-targeted antisense therapy (Oblimersen sodium): towards clinical reality. Rev Recent Clin Trials. 2006;1:217–235
  62. Tarhini AA, Kirkwood JM. Oblimersen in the treatment of metastatic melanoma. Future Oncol. 2007;3:263–271
  63. Varker KA, Biber JE, Kefauver C, et al. A randomized phase 2 trial of bevacizumab with or without daily low-dose interferon alfa-2b in metastatic malignant melanoma. Ann Surg Oncol. 2007;14:2367–2376
  64. Tarhini AA, Kirkwood JM. Tremelimumab, a fully human monoclonal IgG2 antibody against CTLA4 for the potential treatment of cancer. Curr Opin Mol Ther. 2007;9:505–514
  65. Lens M, Ferrucci PF, Testori A. Anti-CTLA4 monoclonal antibody ipilimumab in the treatment of metastatic melanoma: recent findings. Recent Patents Anticancer Drug Discov. 2008;3:105–113
  66. Marti RM, Mayorga ME, Llecha N, et al. Expression of somatostatin receptors (SSTR) in melanoma cell lines (Effect of somatostatin analogues on their proliferation). Arch Dermatol Res. 2007;299:290

PII: S0740-2570(08)00062-2

doi: 10.1053/j.semdp.2008.07.008

Seminars in Diagnostic Pathology
Volume 25, Issue 4 , Pages 262-273 , November 2008

Article Tools

* Image Usage & Resolution